Advertisement Daiichi Sankyo signs deal to market AstraZeneca's FluMist in Japan - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Daiichi Sankyo signs deal to market AstraZeneca’s FluMist in Japan

AstraZeneca has granted Daiichi Sankyo an exclusive license to market its FluMist Quadrivalent in Japan.

Daiichi Sankyo will pay AstraZeneca an undisclosed upfront fee as well as development milestones and sales-associated payments after its launch.

The Japanese firm will also take full responsibility for future development and commercialization of FluMist in the country.

AstraZeneca chief financial officer and senior executive team member responsible for Japan Marc Dunoyer said: "We’re pleased to enter into this agreement with Daiichi Sankyo, whose specific expertise in developing and commercialising innovative vaccines will help ensure we bring FluMist Quadrivalent to as many children as possible in Japan."

Daiichi Sankyo member of the board & head of vaccine business unit Takeshi Ogita said: "We are proud to be able to deliver, once approved, FluMist Quadrivalent to Japanese children and adolescents and to make a contribution to public health by protecting people from influenza."

FluMist, originally approved in the US in 2003, is a live attenuated influenza vaccine which is administered as a nasal spray and features four protective strains. Over 100 million doses of FluMist have been distributed globally.

Preferential recommendations for live attenuated influenza vaccine (LAIV) have been implemented in the UK, Canada, Israel, Finland, Sweden (high-risk individuals) and Germany (high-risk individuals).

A general recommendation for quadrivalent LAIV in people aged two to 49 has been adopted in the US.